Chemomab Announces Positive Phase 2 Nebakitug Clinical Data in PSC at DDW 2025
Chemomab Therapeutics announced positive Phase 2 SPRING trial data for nebokitug (CM-101) in primary sclerosing cholangitis (PSC) at Digestive...
FDA Grants Fast Track to Alterity’s ATH434 for Multiple System Atrophy
Alterity Therapeutics has received Fast Track designation from the U.S. FDA for ATH434, a treatment for Multiple System Atrophy...
Stem Cell Therapy for Alzheimer’s: Phase 1 Trial Data at ISCT 2025
Regeneration Biomedical, Inc. (RBI) announced positive interim results from its Phase 1 clinical trial of a novel Alzheimer’s diseaseAlzheimer’s...
Dianthus Completes Phase 2 Trial Enrollment: Top-Line Results Expected
Dianthus Therapeutics has completed enrollment in its Phase 2 MaGic trial of DNTH103 for generalized Myasthenia Gravis (gMG), exceeding...
Guided, Then Penalized: A Deep Dive into the FDA’s MDMA Ruling and What it Means for Psychedelic Clinical Trials
In August 2024, the FDA rejected the New Drug Application for MDMA-assisted therapy for PTSD, sponsored by Lykos Therapeutics,...
Inquis Medical’s AVENTUS Thrombectomy System Safe, Effective for PE
Inquis Medical announced positive results from its AVENTUS IDE trial, evaluating the safety and efficacy of its AVENTUS Thrombectomy...
Reshape Lifesciences Presents Pre-Clinical Data on Diabetes Neuromodulation Device
ReShape Lifesciences presented pre-clinical data on its Diabetes Neuromodulation device at the 12th Annual Minnesota Neuromodulation Symposium. The device,...
Theratechnologies at ACTHIV 2025: Managing Excess Visceral Abdominal Fat in HIV
Theratechnologies presented two posters at the 19th Annual American Conference for the Treatment of HIV (ACTHIV 2025), focusing on...
Endogenex Highlights 48-Week Regent-1 Study Results at DDW 2025
Endogenex, a medical device company, presented positive clinical trial data for its ReCET System, a novel endoscopic procedure for...
Rec-4881 FAP Study Shows Reduced Polyp Burden
Recursion Pharmaceuticals announced preliminary results from its Phase 1b/2 TUPELO trial of REC-4881, a MEK1/2 inhibitor for Familial Adenomatous...